Evidence map›Paper›PMID 37074437›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Stunting Following Moderate-to-Severe Diarrhea Among Children Aged <5 Years in Africa Before and After Rotavirus Vaccine Introduction: A Comparison of the Global Enteric Multicenter Study and the Vaccine Impact on Diarrhea in Africa (VIDA) Study.

Dilruba Nasrin, Yuanyuan Liang, Jennifer R Verani, Helen Powell, Samba O Sow, Richard Omore, M Jahangir Hossain, Sanogo Doh, Syed M A Zaman, Joquina Chiquita M Jones and 5 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Article
  4. Shigella in Africa: New Insights From the Vaccine Impact on Diarrhea in Africa (VIDA) Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

Dilruba NasrinDepartment of Medicine, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Yuanyuan LiangDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Jennifer R VeraniDivision of Global Health Protection, US Centers for Disease Control and Prevention, Nairobi, Kenya.
Helen PowellDepartment of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Samba O SowCentre pour le Développement des Vaccins du Mali, Bamako, Mali.
Richard OmoreKenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.
M Jahangir HossainMedical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Sanogo DohCentre pour le Développement des Vaccins du Mali, Bamako, Mali.
Syed M A ZamanMedical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Joquina Chiquita M JonesMedical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.
Alex O AwuorKenya Medical Research Institute, Center for Global Health Research, Kisumu, Kenya.
Irene N KasumbaDepartment of Medicine, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Sharon M TennantDepartment of Medicine, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Usha RamakrishnanHubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Karen L KotloffDepartment of Medicine, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
University of Maryland, Baltimore · USMRC Unit the Gambia · GMCentre Pour le Développement des Vaccins-Mali · MLKenya Medical Research Institute · KECenters for Disease Control and Prevention · KEEmory University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStudies conducted before rotavirus vaccine introduction found that moderate-to-severe diarrhea (MSD) in children aged <5 years was associated with stunting at follow-up. It is unknown whether the reduction in rotavirus-associated MSD following vaccine introduction decreased the risk of stunting.

methodsThe Global Enteric Multicenter Study (GEMS) and the Vaccine Impact on Diarrhea in Africa (VIDA) study, two comparable matched case-control studies, were conducted during 2007-2011 and 2015-2018, respectively. We analyzed data from 3 African sites where rotavirus vaccine was introduced after GEMS and before starting VIDA. Children with acute MSD (<7 days onset) were enrolled from a health center and children without MSD (diarrhea-free for ≥7 days) were enrolled at home within 14 days of the index MSD case. The odds of being stunted at a follow-up visit 2-3 months after enrollment for an episode of MSD was compared between GEMS and VIDA using mixed-effects logistic regression models controlling for age, sex, study site, and socioeconomic status.

resultsWe analyzed data from 8808 children from GEMS and 10 579 from VIDA. Among those who were not stunted at enrollment in GEMS, 8.6% with MSD and 6.4% without MSD became stunted during the follow-up period. In VIDA, 8.0% with MSD and 5.5% children without MSD developed stunting. An episode of MSD was associated with higher odds of being stunted at follow-up compared with children without MSD in both studies (adjusted odds ratio [aOR], 1.31; 95% confidence interval [CI]: 1.04-1.64 in GEMS and aOR, 1.30; 95% CI: 1.04-1.61 in VIDA). However, the magnitude of association was not significantly different between GEMS and VIDA (P = .965).

conclusionsThe association of MSD with subsequent stunting among children aged <5 years in sub-Saharan Africa did not change after rotavirus vaccine introduction. Focused strategies are needed for prevention of specific diarrheal pathogens that cause childhood stunting.

Indexed as

RotavirusRotavirus VaccinesAfrica South of the SaharaChildDiarrheaGrowth DisordersHumansInfantRotavirus VaccineschildrendiarrheaGEMSstuntingVIDA

Identifiers

PMID37074437
PMCPMC10116564
OpenAlexW4366351450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.